AI Science Tracker

Prospective Swedish cohort validates multimodal AI prostate-biopsy biomarker for recurrence and adverse pathology after prostatectomy

Skåne University Hospital; Lund University; Artera Inc.; University of California, San Francisco · 21 Feb 2025 · medicine

Discovery

Prospective Swedish cohort validates multimodal AI prostate-biopsy biomarker for recurrence and adverse pathology after prostatectomy

A previously developed multimodal AI score was retrospectively applied to archived diagnostic biopsies and follow-up from a prospectively collected Swedish prostatectomy cohort. The score, derived from digitized diagnostic prostate-biopsy images plus age, PSA and clinical T-stage, was associated with post-surgical biochemical recurrence and adverse pathology. Among 143 men with evaluable data and median 8.8-year follow-up, the continuous score was associated with recurrence (subdistribution HR 2.45, 95% CI 1.77–3.38); among 88 evaluable for adverse pathology, OR was 4.85 (95% CI 2.54–10.78). Estimated 5-year recurrence was 25% in intermediate/high score versus 4% in low score.

Technology: Artera multimodal artificial-intelligence (MMAI) prostate biomarker combining deep-learning features from digitized biopsy histopathology with age, PSA and clinical T-stage

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: A previously developed multimodal AI score was retrospectively applied to archived diagnostic biopsies and follow-up from a prospectively collected Swedish prostatectomy cohort.
  • Still unknown: This is retrospective external prognostic validation using specimens and follow-up from a prospectively collected cohort; it is not prospective AI-guided care, a randomized test of biomarker-guided treatment, or evidence that using the score improves outcomes. Only 143 patients had evaluable images and complete covariates, and 88 were evaluable for adverse pathology; it is a single tertiary Swedish center. The model’s earlier development setting involved men receiving radiation in North America, so this tests transport to a different population/treatment context. A 2025 conference abstract describing this cohort is an earlier presentation of the same study, not another record.
  • AI role: The locked MMAI score converted diagnostic biopsy images and clinical variables into patient-level prognostic scores. The prospective Swedish cohort tested whether that model-derived score associated with the distinct post-prostatectomy outcomes biochemical recurrence and adverse pathology; associations persisted after adjustment for standard NCCN/CAPRA clinical risk measures.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11995000/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 25 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.